Search
Research Committee call for interest
The overarching aim of the Research Committee is to further strengthen EHA’s interactions with and relevance for the wider hematological research community.
Read moreSponsor and Fundraising Committee
Current committee members
Martin Dreyling, Germany (Chair (EHA Board))
Antonio Pierini, Italy (Vice Chair (non-Board member))
Igor Aurer, Croatia (Representative, SWG Committee)
Mariane de Montalembert, France (Councilor)
Konstanze Döhner, Germany (EHA Board)
Kirsten Gronbaek, Denmark (EHA Board)
Frank Leebeek, The Netherlands (Councilor)
David Rees, United Kingdom (Representative, Education…
Implementation of the new EU Regulation for In Vitro Diagnostic Medical Devices: a ticking time bomb for the diagnostic sector.
Urgent actions are needed now to prevent a collapse of diagnostic testing.
Read moreEHA-EMBL/EBI Computational Biology Training in Hematology
The CBTH 2025 call for applications is now closed.
Read moreYoung EHA Committee
Current committee members
Nuno Borges, United Kingdom (Chair)
Alba Maiques Diaz, Spain (Vice-Chair)
Elizabeth Macintyre, France (EHA Past President)
Regular members
Franziska Auer, USA/Germany
Anna Avagyan, Armenia
Côme Bommier, France
Lorenzo Brunetti, Italy
Eleni Gavriilaki, Greece
Ruxandra Irimia, Romania
Rafal Machowicz, Poland
Pedro Moura, Sweden
Rhiannon Newman, Finland
Marlies Vanden Bempt, Belgium
Carlo Zaninetti, Germany
AimYoung…
Highlights from the SWG
The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.
Read moreTARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS
Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.
Read moreHematopoietic stem cells: New results to be presented at the 18th Congress of the EHA
During ageing, this fine-tuned regulatory network may become altered, leading to abnormal HSC regulation. The functional quality of HSCs decreases with age partly due to an accumulation of damaged DNA, leading to an increased incidence of hematological malignancies.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- »